Ozempic maker Novo Nordisk posts strong results but competition weighs / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File
-
How Mystery Bounty Poker Tournaments Spread from Curiosity to Mainstream
-
Inflation Breach and Bond Yields Spark Rate Hike Fears for December
-
Market Buzz: Meesho Stake Sale, Clean Max’s ₹50,000 Crore Investment and Corporate Updates
-
The 20 Most Shocking Documentaries Ranked: From Elizabeth Holmes to Man on Wire
-
Below Deck alumnus João Franco and brother arrested after fatal Turkey fight
-
Ole Miss inquiry expands after video and monkey-noise allegations
-
General Hospital actor Randall England dies at 75
-
Bunnie XO artwork taken down from Jelly Roll’s Nashville bar
-
London museum removes Russell Brand hair exhibit after rape conviction
-
Arlington sentinel rebukes Pete Hegseth entourage for laughter near memorial
-
Yella Beezy sentenced to life for arranging rapper Mo3’s murder
-
Late Late Show Line-Up Announced Featuring Nicola Coughlan and TJ Reid
-
Kylie Jenner employee describes closet ordeal and pepper-spray incident
-
Authorities to identify Montauk Mary and five other Long Island cold-case victims
-
Davante Adams injury deepens Los Angeles Rams receiver shortage
-
Barbie sequel negotiations stall over reported $25 million pay packages
-
João Franco’s earlier post draws attention after arrest over fatal Turkey brawl
-
Bath & Body Works launches buy-one-get-one-free candle offer
-
Nvidia Appoints Colette Kress as Interim CEO Following Jensen Huang’s Resignation
-
Calgary Chef Launches App to Connect Food Businesses with Non-Profits
-
Itlu Arjuna receives U/A certificate ahead of theatrical release
-
Palestinian Artist Masada Sabat Uses Oil Paint to Carry Homeland’s Story
-
Dhananjaya de Silva guides Sri Lanka to 221-4 against Pakistan
-
Niraj Kumar earns Los Angeles Olympic quota with 50m rifle bronze
-
Parents of Deceased Model Fight to Maintain $4 Million Judgment Against Shawne Merriman Associate
-
Delhi gold loses Rs 800 while silver falls Rs 5,000
-
India extends micro-credit guarantee plan for five years
-
Pradeep Antony, Smeha Manimegalai portray secret spouses in Mr & Mrs Office
-
Zelenskyy arrives in Dublin for meetings on Ukraine and peace efforts
-
Woman barred from every Greggs outlet after series of offences
-
Jury hears social-media image helped identify teen in Scarlett Faulkner case
-
Ketchup packets link suspect to break-in at Eddie Rocket’s restaurant
-
American Airlines passenger falls ill and vomits on three travellers
-
Spain's General Strike Links Housing Crisis to Lost Purchasing Power
-
US Inflation Broadens as Fed Officials Consider Faster Rate Hikes
-
China's Singles' Day Exposes Persistent Consumer Caution
-
China's Trade Surplus Passes $1 Trillion as Technology Exports Surge
-
OPEC Says Oil Output Is Near Prewar Levels Despite Shipping Disruptions
-
Energy Costs Push OECD Inflation Up to 4.5%
-
Bank of England Raises Interest Rate to 4% as Energy Risks Intensify
-
US Adds 165,000 Jobs as Unemployment Falls to 4.1%
-
China's Factory Inflation Accelerates While Consumer Demand Stays Weak
-
Euro-Area Inflation Reaches 4% as Energy Prices Jump
-
Irish police prepare for further hoax bomb threats after hundreds of schools targeted
Ozempic maker Novo Nordisk posts strong results but competition weighs
Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition is weighing on sales of its diabetes and obesity treatments Ozempic and Wegovy in the United States.
The group reported a net profit of 26.5 billion kroner ($4.1 billion), a 32 percent increase from the same period last year, while sales increased by 18 percent to 76 billion kroner.
The drug maker lowered its annual earnings outlook last week, causing its share price to continue its nearly year-long slide.
The company had already cut its forecast in May and announced the departure of its chief executive Lars Fruergaard Jorgensen.
"In May we mostly thought the bottom was reached," Mikael Bak, director of the Danish shareholders' association, told AFP.
Bak said "every is a bit surprised" that the situation has deteriorated.
"So now we don't want to see more disappointments, there are reasons to believe the business is healthy, the institution and the products good," he said.
Novo Nordisk announced last week that it was promoting Maziar Mike Doustdar, its vice president for international operations, to succeed Jorgensen.
The popularity of Novo Nordisk's weight-loss treatments had once made it a darling of investors, boosting its share price and at one point making it Europe's most valuable company.
But it now faces growing competition from rival treatments made by US group Eli Lilly in United States.
A rule by the US Food and Drug Administration allowing pharmacies to create so-called "compound" copycat versions of the drug, after high demand led to shortages, has also dented Novo Nordisk's earnings.
S.Leonhard--VB